In this issue:
- Children with acute hepatitis of unknown cause
- Patient-reported outcomes in HCV infection in real-world practice
- DAAs in patients with malignancies other than liver cancer
- Glecaprevir/pibrentasvir in HCV-infected individuals with active drug use
- Safety analysis of glecaprevir/pibrentasvir in advanced liver disease
- 8- vs 12-weeks of glecaprevir/pibrentasvir for HCV and compensated cirrhosis
- Long-term persistence of HCV resistance-associated substitutions
- Retreatment for HCV DAA therapy virological failure
- DAA therapy for HCV in elderly patients
- Internet-guided HCV-RNA testing
Please login below to download this issue (PDF)